

# CITATION REPORT

List of articles citing

**Structure of the VHL-ElonginC-ElonginB complex:  
implications for VHL tumor suppressor function**

**DOI: 10.1126/science.284.5413.455**  
**Science, 1999, 284, 455-61.**

**Source:** <https://exaly.com/paper-pdf/30674097/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
749	.		
748	Aberrant protein folding as the molecular basis of cancer. <b>2003</b> , 232, 67-76		25
747	Germline and somatic mutations in von Hippel-Lindau disease gene and its significance in the development of kidney cancer. <b>1999</b> , 128, 1-10		13
746	Binding of elongin A or a von Hippel-Lindau peptide stabilizes the structure of yeast elongin C. <b>1999</b> , 96, 9033-8		23
745	Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbCH7. <b>1999</b> , 274, 31707-12		272
744	VHL: a very hip ligase. <b>1999</b> , 96, 12230-2		43
743	The von Hippel-Lindau tumor suppressor gene product promotes, but is not essential for, NEDD8 conjugation to cullin-2. <b>1999</b> , 274, 36025-9		25
742	SCF and Cullin/Ring H2-based ubiquitin ligases. <b>1999</b> , 15, 435-67		1096
741	von Hippel-Lindau protein induces hypoxia-regulated arrest of tyrosine hydroxylase transcript elongation in pheochromocytoma cells. <b>1999</b> , 274, 30109-14		38
740	Cancer. Many vessels, faulty gene. <b>1999</b> , 399, 203-4		44
739	CUL-2 is required for the G1-to-S-phase transition and mitotic chromosome condensation in <i>Caenorhabditis elegans</i> . <b>1999</b> , 1, 486-92		108
738	Role of endothelial cell survival and death signals in angiogenesis. <b>1999</b> , 3, 101-16		45
737	The F-box: a new motif for ubiquitin dependent proteolysis in cell cycle regulation and signal transduction. <b>1999</b> , 72, 299-328		223
736	Towards the three-dimensional structure of voltage-gated potassium channels. <b>1999</b> , 24, 345-9		41
735	Paper Alert. <b>1999</b> , 7, R149-R153		
734	Urological malignancies and the proteomic-genomic interface. <b>1999</b> , 20, 3629-37		20
733	Altered states: programmed proteolysis and the budding yeast cell cycle. <b>1999</b> , 2, 610-7		6

732	Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. <b>1999</b> , 4, 1051-61	196
731	How the cyclin became a cyclin: regulated proteolysis in the cell cycle. <b>1999</b> , 97, 431-4	388
730	Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. <b>1999</b> , 96, 12436-41	411
729	Regulation of mammalian O <sub>2</sub> homeostasis by hypoxia-inducible factor 1. <b>1999</b> , 15, 551-78	1571
728	Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isoforms. <b>1999</b> , 263, 491-7	78
727	An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. <b>1999</b> , 266, 43-50	47
726	Angiogenesis: how a tumor adapts to hypoxia. <b>1999</b> , 266, 718-22	324
725	The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. <b>1999</b> , 13, 1822-33	294
724	Bibliography Current World Literature. <b>2000</b> , 12, B79-B133	
723	Novel mutations of the von Hippel-Lindau tumor-suppressor gene and rare DNA hypermethylation in renal-cell carcinoma cell lines of the clear-cell type. <b>2000</b> , 87, 650-653	21
722	Voltage dependent activation of potassium channels is coupled to T1 domain structure. <b>2000</b> , 7, 403-7	89
721	Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila. <b>2000</b> , 19, 2803-11	52
720	Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. <b>2000</b> , 19, 5435-43	306
719	Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. <b>2000</b> , 2, 423-7	1247
718	VHL takes HIF's breath away. <b>2000</b> , 2, E121-3	48
717	Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. <b>2000</b> , 408, 381-6	487
716	Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: an extended study of 77 families. <b>2000</b> , 91, 204-12	37
715	The suppressors of cytokine signaling (SOCS) proteins: important feedback inhibitors of cytokine action. <b>2000</b> , 28, 1105-12	65

714	Adapting to multiple personalities: Cbl is also a RING finger ubiquitin ligase. <b>2000</b> , 1471, M1-M12	12
713	Potassium channel structure: domain by domain. <b>2000</b> , 10, 456-61	42
712	The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. <b>2000</b> , 10, 429-39	543
711	Genetic basis of intramedullary spinal cord tumors and therapeutic implications. <b>2000</b> , 47, 239-51	22
710	Inherited epithelial tumors of the kidney: old and new diseases. <b>2000</b> , 10, 313-8	15
709	Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. <b>2000</b> , 19, 4298-309	657
708	Regulation of transcription factors by protein degradation. <b>2000</b> , 57, 1207-19	74
707	Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. <b>2000</b> , 23, 1-22; discussion 23-4	122
706	HIF-1: mediator of physiological and pathophysiological responses to hypoxia. <b>2000</b> , 88, 1474-80	1594
705	The conserved RING-H2 finger of ROC1 is required for ubiquitin ligation. <b>2000</b> , 275, 15432-9	54
704	Structure of GATE-16, membrane transport modulator and mammalian ortholog of autophagocytosis factor Aut7p. <b>2000</b> , 275, 25445-50	119
703	von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. <b>2000</b> , 5 Suppl 1, 32-6	49
702	Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products. <b>2000</b> , 97, 8507-12	92
701	Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. <b>2000</b> , 275, 20700-6	70
700	Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. <b>2000</b> , 37, 348-53	42
699	The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. <b>2000</b> , 20, 1382-93	92
698	Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. <b>2000</b> , 97, 10430-5	545
697	Suppressor of cytokine signaling-1 inhibits VAV function through protein degradation. <b>2000</b> , 275, 14005-8	139

696	Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. <b>2000</b> , 275, 25733-41		819
695	Signaling and transcription in T helper development. <b>2000</b> , 18, 451-94		548
694	Drosophila von Hippel-Lindau tumor suppressor complex possesses E3 ubiquitin ligase activity. <b>2000</b> , 276, 355-61		24
693	Comparative sequence analysis of the VHL tumor suppressor gene. <b>2000</b> , 65, 253-65		42
692	Negative regulation of cytokine signaling pathways. <b>2000</b> , 18, 143-64		506
691	Ubiquitin-like proteins: new wines in new bottles. <b>2000</b> , 248, 1-14		418
690	Tumor suppressor genes. <b>2000</b> , 10, 81-93		127
689	Proteolysis and the cell cycle: with this RING I do thee destroy. <b>2000</b> , 10, 54-64		272
688	Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. <b>2000</b> , 101, 259-70		498
687	Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. <b>2000</b> , 106, 425-31		60
686	Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2. <b>2000</b> , 275, 8991-9000		31
685	Renal toxicity and carcinogenicity of trichloroethylene: key results, mechanisms, and controversies. <b>2000</b> , 30, 253-85		100
684	Biophysical characterization of elongin C from <i>Saccharomyces cerevisiae</i> . <i>Biochemistry</i> , <b>2000</b> , 39, 11137-46		8
683	HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. <i>Science</i> , <b>2001</b> , 292, 464-8	33.3	3742
682	von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. <i>Human Molecular Genetics</i> , <b>2001</b> , 10, 1019-27	5.6	285
681	A modular polycistronic expression system for overexpressing protein complexes in <i>Escherichia coli</i> . <b>2001</b> , 21, 224-34		178
680	Human cytotrophoblast expression of the von Hippel-Lindau protein is downregulated during uterine invasion in situ and upregulated by hypoxia in vitro. <b>2001</b> , 233, 526-36		66
679	The von Hippel-Lindau tumor suppressor gene. <b>2001</b> , 264, 117-25		183

678	The UBX domain: a widespread ubiquitin-like module. <b>2001</b> , 307, 17-24	119
677	Solution structure and interaction surface of the C-terminal domain from p47: a major p97-cofactor involved in SNARE disassembly. <b>2001</b> , 311, 255-63	76
676	Solution structure and dynamics of yeast elongin C in complex with a von Hippel-Lindau peptide. <b>2001</b> , 312, 177-86	25
675	Review: cellular substrates of the eukaryotic chaperonin TRiC/CCT. <b>2001</b> , 135, 176-84	122
674	Molecular characterization of pancreatic serous microcystic adenomas: evidence for a tumor suppressor gene on chromosome 10q. <b>2001</b> , 158, 317-21	89
673	The von Hippel-Lindau tumor suppressor protein. <b>2001</b> , 11, 27-34	180
672	Three-dimensional structure of the anaphase-promoting complex. <b>2001</b> , 7, 907-13	67
671	Binding and regulation of HIF-1alpha by a subunit of the proteasome complex, PSMA7. <b>2001</b> , 498, 62-6	51
670	Novel vectors for co-expression of two proteins in E. coli. <b>2001</b> , 31, 322-3, 326-8	55
669	VHL tumor suppressor regulates Cl-/HCO <sub>3</sub> <sup>-</sup> exchange and Na <sup>+</sup> /H <sup>+</sup> exchange activities in renal carcinoma cells. <b>2001</b> , 5, 119-28	36
668	Von Hippel-Lindau disease: gene to bedside. <b>2001</b> , 14, 695-703	31
667	Von Hippel-Lindau disease: clinical and molecular perspectives. <b>2001</b> , 82, 85-105	68
666	Insights into the role of the von Hippel-Lindau gene product. A key player in hypoxic regulation. <b>2001</b> , 9, 235-40	19
665	The ubiquitin-proteasome pathway and proteasome inhibitors. <b>2001</b> , 21, 245-73	351
664	Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region. <b>2001</b> , 91, 457-67	34
663	Mechanisms underlying ubiquitination. <b>2001</b> , 70, 503-33	2894
662	Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. <b>2001</b> , 20, 5197-206	849
661	A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (1alpha, 2alpha and 3alpha). <b>2001</b> , 20, 1435-44	65

660	VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium. <b>2001</b> , 20, 5393-400		43
659	Maintenance of an unfolded polypeptide by a cognate chaperone in bacterial type III secretion. <b>2001</b> , 414, 77-81		252
658	Integration of genome data and protein structures: prediction of protein folds, protein interactions and "molecular phenotypes" of single nucleotide polymorphisms. <b>2001</b> , 11, 125-30		47
657	The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. <b>2001</b> , 276, 43611-7		144
656	Endoplasmic reticulum stress prolongs GH-induced Janus kinase (JAK2)/signal transducer and activator of transcription (STAT5) signaling pathway. <b>2001</b> , 15, 1471-83		18
655	A central role for the T1 domain in voltage-gated potassium channel formation and function. <b>2001</b> , 276, 28493-502		38
654	Muf1, a novel Elongin BC-interacting leucine-rich repeat protein that can assemble with Cul5 and Rbx1 to reconstitute a ubiquitin ligase. <b>2001</b> , 276, 29748-53		130
653	Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. <b>2001</b> , 98, 1583-8		333
652	Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. <b>2001</b> , 15, 3104-17		380
651	Genotype-phenotype correlation in von Hippel-Lindau syndrome. <i>Human Molecular Genetics</i> , <b>2001</b> , 10, 763-7	5.6	118
650	von Hippel-Lindau disease: genetic and clinical observations. <b>2001</b> , 28, 131-66		17
649	Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein. <b>2001</b> , 276, 1407-16		43
648	Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumorigenesis in von Hippel-Lindau disease. <i>Human Molecular Genetics</i> , <b>2001</b> , 10, 1029-38	5.6	293
647	The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. <b>2001</b> , 276, 40346-52		49
646	VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. <b>2002</b> , 94, 1569-75		183
645	A molecular basis for stabilization of the von Hippel-Lindau (VHL) tumor suppressor protein by components of the VHL ubiquitin ligase. <b>2002</b> , 277, 30388-93		47
644	Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. <b>2002</b> , 23, 759-68		256
643	Mammalian mediator subunit mMED8 is an Elongin BC-interacting protein that can assemble with Cul2 and Rbx1 to reconstitute a ubiquitin ligase. <b>2002</b> , 99, 10353-8		71

642	Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. <b>2002</b> , 99, 15351-6	162
641	Leu-574 of HIF-1alpha is essential for the von Hippel-Lindau (VHL)-mediated degradation pathway. <b>2002</b> , 277, 41750-5	32
640	CUL-4A is critical for early embryonic development. <b>2002</b> , 22, 4997-5005	78
639	Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. <b>2002</b> , 76, 9194-206	188
638	Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. <b>2002</b> , 277, 4656-62	127
637	Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing. <b>2002</b> , 17, 356-9	13
636	From erythropoietin to oxygen: hypoxia-inducible factor hydroxylases and the hypoxia signal pathway. <b>2002</b> , 20, 445-50	46
635	Analysis of von hippel-lindau mutations with comparative genomic hybridization in sporadic and hereditary hemangioblastomas: possible genetic heterogeneity. <b>2002</b> , 97, 977-82	22
634	VHL2C phenotype in a German von Hippel-Lindau family with concurrent VHL germline mutations P81S and L188V. <b>2002</b> , 87, 5241-6	25
633	Expression of hypoxia inducible factor-1 alpha and correlation with preoperative embolization of meningiomas. <b>2002</b> , 97, 658-67	27
632	Oxygen homeostasis and cancer: insights from a rare disease. <b>2002</b> , 2, 356-62	19
631	Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. <b>2002</b> , 13, 1847-54	215
630	The pressure rises: update on the genetics of pheochromocytoma. <i>Human Molecular Genetics</i> , <b>2002</b> , 11, 2347-54	5.6 123
629	Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter. <b>2002</b> , 39, 463-72	26
628	Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. <b>2002</b> , 22, 1947-60	65
627	Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. <b>2002</b> , 22, 2984-92	133
626	Recurrent polytopic chromaffin paragangliomas in a 9-year-old boy resulting from a novel germline mutation in the von Hippel-Lindau gene. <b>2002</b> , 24, 145-8	7
625	Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. <b>2002</b> , 99, 3562-5	67



624	The von Hippel-Lindau tumor suppressor complex and regulation of hypoxia-inducible transcription. <b>2002</b> , 85, 1-12	12
623	Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. <b>2002</b> , 22, 5319-36	142
622	Initiation of eukaryotic DNA replication: regulation and mechanisms. <b>2002</b> , 72, 41-94	38
621	Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. <b>2002</b> , 294, 700-9	101
620	Structure and function of a protein folding machine: the eukaryotic cytosolic chaperonin CCT. <b>2002</b> , 529, 11-6	158
619	Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. <b>2002</b> , 77, 44-56	64
618	Structure of GABARAP in two conformations: implications for GABA(A) receptor localization and tubulin binding. <b>2002</b> , 33, 63-74	121
617	Identification of protein disulfide isomerase as an endothelial hypoxic stress protein. <b>2002</b> , 282, L996-1003	33
616	Playing Tag with HIF: The VHL Story. <b>2002</b> , 2, 131-135	32
615	Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. <b>2002</b> , 1, 237-46	626
614	Structural basis of ubiquitylation. <b>2002</b> , 12, 822-30	50
613	Regulation of gene expression for neurotransmitters during adaptation to hypoxia in oxygen-sensitive neuroendocrine cells. <b>2002</b> , 59, 178-87	24
612	Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. <b>2002</b> , 95, 47-53	63
611	von Hippel-Lindau tumor suppressor protein represses platelet-derived growth factor B-chain gene expression via the Sp1 binding element in the proximal PDGF-B promoter. <b>2002</b> , 85, 490-5	15
610	Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. <b>2002</b> , 34, 58-68	174
609	Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney. <b>2002</b> , 35, 359-64	22
608	Oxygen mediated gene regulation. <b>2002</b> , 7, S21-S25	1
607	The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. <b>2002</b> , 21, 3507-16	48

606	Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. <b>2002</b> , 417, 975-8	550
605	Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. <b>2002</b> , 416, 703-9	1145
604	Hypoxia--a key regulatory factor in tumour growth. <b>2002</b> , 2, 38-47	4026
603	Molecular basis of the VHL hereditary cancer syndrome. <b>2002</b> , 2, 673-82	670
602	Siah ubiquitin ligase is structurally related to TRAF and modulates TNF-alpha signaling. <b>2002</b> , 9, 68-75	113
601	Oxygen mediated gene regulation. <b>2002</b> , 7, S21-S25	3
600	Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. <i>Science</i> , <b>2002</b> , 296, 1886-9	33-3 580
599	Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. <b>2002</b> , 99, 13459-64	471
598	A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. <b>2002</b> , 80, 562-75	73
597	A phase II study of thalidomide in advanced metastatic renal cell carcinoma. <b>2002</b> , 20, 389-93	36
596	Anti-angiogenic therapy: rationale, challenges and clinical studies. <b>2002</b> , 5, 237-56	108
595	The SOCS box: a tale of destruction and degradation. <b>2002</b> , 27, 235-41	347
594	The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. <b>2003</b> , 22, 1857-67	63
593	HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. <b>2003</b> , 22, 4082-90	997
592	Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. <b>2003</b> , 22, 4249-59	71
591	Role of hypoxia in tumor angiogenesis-molecular and cellular angiogenic crosstalk. <b>2003</b> , 314, 145-55	40
590	Molecular basis of inherited diseases: a structural perspective. <b>2003</b> , 19, 505-13	86
589	Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. <b>2003</b> , 105, 190-5	28

588	Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8. <b>2003</b> , 422, 330-4	171
587	The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase. <b>2003</b> , 425, 311-6	343
586	BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3. <b>2003</b> , 425, 316-21	383
585	von Hippel-Lindau protein complex is regulated by cell density. <b>2003</b> , 22, 5270-80	13
584	Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. <b>2003</b> , 35, 229-37	62
583	Genetic disorders and renal cell carcinoma. <b>2003</b> , 30, 133-41	14
582	Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. <i>Science</i> , <b>2003</b> , 302, 1056-60	33-3 974
581	Angiogenesis as a new target for cancer control. <b>2003</b> , 1, 1-12	16
580	Molecular cloning and characterization of the human ASB-8 gene encoding a novel member of ankyrin repeat and SOCS box containing protein family. <b>2003</b> , 300, 972-9	23
579	Protein production in <i>Escherichia coli</i> for structural studies by X-ray crystallography. <b>2003</b> , 142, 133-43	59
578	Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. <b>2003</b> , 11, 1445-56	501
577	Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding. <b>2003</b> , 12, 1213-24	89
576	Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. <b>2003</b> , 12, 1551-64	211
575	A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1). <b>2003</b> , 16, 115-24	52
574	Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product. <b>2003</b> , 278, 6816-23	45
573	GABARAP: lessons for synaptogenesis. <b>2003</b> , 9, 205-16	23
572	A role for <i>Saccharomyces cerevisiae</i> Cul8 ubiquitin ligase in proper anaphase progression. <b>2003</b> , 278, 22828-37	40
571	Pheochromocytoma: the expanding genetic differential diagnosis. <b>2003</b> , 95, 1196-204	199

570	High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil. <b>2003</b> , 40, e31	20
569	von Hippel-Lindau disease: recent advances and therapeutic perspectives. <b>2003</b> , 3, 215-33	14
568	Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. <b>2003</b> , 278, 31972-9	85
567	Tumor Suppressor Genes. <b>2003</b> ,	1
566	Renal Cell Carcinoma: The Human Disease. <b>2003</b> , 451-460	
565	Characterization of the last subunit of the Arabidopsis COP9 signalosome: implications for the overall structure and origin of the complex. <b>2003</b> , 15, 719-31	48
564	The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. <b>2003</b> , 14, 2703-11	94
563	Angiogenesis in endocrine tumors. <b>2003</b> , 24, 600-32	218
562	Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. <b>2003</b> , 278, 11032-40	214
561	VHL and kidney cancer. <b>2003</b> , 222, 167-83	21
560	Clinical review 155: Pheochromocytoma in Von Hippel-Lindau disease. <b>2003</b> , 88, 969-74	65
559	Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. <b>2003</b> , 8, d100-16	54
558	Ubiquitin-protein ligases--novel therapeutic targets?. <b>2004</b> , 5, 163-76	17
557	Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of oxygen sensing. <b>2004</b> , 381, 320-35	9
556	Von Hippel-Lindau disease. <b>2004</b> , 4, 833-42	91
555	Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. <b>2004</b> , 286, R977-88	175
554	Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression. <b>2004</b> , 100, 488-97	25
553	Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. <b>2004</b> , 18, 2861-6	246

552	pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. <b>2004</b> , 24, 3251-61	150
551	Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. <b>2004</b> , 18, 2867-72	256
550	Tumor suppressor von Hippel-Lindau (VHL) stabilization of Jade-1 protein occurs through plant homeodomains and is VHL mutation dependent. <b>2004</b> , 64, 1278-86	52
549	Solution structure of a ubiquitin-like domain from tubulin-binding cofactor B. <b>2004</b> , 279, 46787-93	26
548	A facile method for high-throughput co-expression of protein pairs. <b>2004</b> , 3, 934-8	89
547	Both BC-box motifs of adenovirus protein E4orf6 are required to efficiently assemble an E3 ligase complex that degrades p53. <b>2004</b> , 24, 9619-29	88
546	Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer. <b>2004</b> , 24, 1-13	101
545	A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred. <b>2004</b> , 13, 401	2
544	Abl oncogene bypasses normal regulation of Jak/STAT activation. <b>2004</b> , 3, 1486-8	16
543	The von Hippel-Lindau tumor suppressor protein is a molten globule under native conditions: implications for its physiological activities. <b>2004</b> , 279, 17190-6	30
542	Identification of Elongin C and Skp1 sequences that determine Cullin selection. <b>2004</b> , 279, 43019-26	10
541	Role of VHL gene mutation in human cancer. <b>2004</b> , 22, 4991-5004	776
540	VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. <b>2004</b> , 18, 3055-65	349
539	Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. <b>2004</b> , 6, 1003-9	291
538	Searching for the hereditary causes of renal-cell carcinoma. <b>2004</b> , 4, 381-93	151
537	The SCF ubiquitin ligase: insights into a molecular machine. <b>2004</b> , 5, 739-51	862
536	Structural basis of the interaction between the AAA ATPase p97/VCP and its adaptor protein p47. <b>2004</b> , 23, 1030-9	154
535	Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. <b>2004</b> , 23, 1681-7	299

534	Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity. <b>2004</b> , 23, 2315-23	12
533	Protein Degradation: CUL-3 and BTB Partners in Proteolysis. <b>2004</b> , 14, R59-R61	36
532	APC/C and SCF: controlling each other and the cell cycle. <b>2004</b> , 14, R787-96	222
531	Ubiquitin: structures, functions, mechanisms. <b>2004</b> , 1695, 55-72	931
530	A hitchhiker's guide to the cullin ubiquitin ligases: SCF and its kin. <b>2004</b> , 1695, 133-70	365
529	Focus on kidney cancer. <b>2004</b> , 6, 223-8	105
528	Endocrine tumor syndromes in infancy and childhood. <b>2004</b> , 15, 223-6	5
527	Combination of multiple alignment analysis and surface mapping paves a way for a detailed pathway reconstruction—the case of VHL (von Hippel-Lindau) protein and angiogenesis regulatory pathway. <b>2004</b> , 13, 786-96	10
526	Neuro-ophthalmology of von Hippel-Lindau. <b>2004</b> , 4, 384-90	2
525	Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. <i>Human Mutation</i> , <b>2004</b> , 24, 215-24	4-7 69
524	Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. <b>2004</b> , 117, 219-48	39
523	Ubiquitin ligases and the immune response. <b>2004</b> , 22, 81-127	237
522	SCC-112, a novel cell cycle-regulated molecule, exhibits reduced expression in human renal carcinomas. <b>2004</b> , 328, 187-96	17
521	Targeting hypoxia tolerance in cancer. <b>2004</b> , 7, 25-40	68
520	General co-expression vectors for the overexpression of heterodimeric protein complexes in <i>Escherichia coli</i> . <b>2004</b> , 38, 1-8	29
519	v-Abl signaling disrupts SOCS-1 function in transformed pre-B cells. <b>2004</b> , 15, 329-41	33
518	von Hippel-Lindau tumor suppressor: not only HIF's executioner. <b>2004</b> , 10, 146-9	60
517	Ozz-E3, a muscle-specific ubiquitin ligase, regulates beta-catenin degradation during myogenesis. <b>2004</b> , 6, 269-82	76

516	Back to the future with ubiquitin. <b>2004</b> , 116, 181-90	585
515	Phacomatoses et il. <b>2004</b> , 1, 1-11	
514	The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. <b>2004</b> , 287, F1-6	54
513	Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomas. <b>2004</b> , 2, 93-7	1
512	Von hippel-lindau disease. <b>2005</b> , 3, 171-8	13
511	Structure and Function of the Cytosolic Chaperonin CCT. 725-755	14
510	Multiple roles of Rbx1 in the VBC-Cul2 ubiquitin ligase complex. <b>2005</b> , 10, 679-91	18
509	The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. <b>2005</b> , 7, 698-705	185
508	Function and regulation of cullin-RING ubiquitin ligases. <b>2005</b> , 6, 9-20	1620
507	The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. <b>2005</b> , 24, 4433-41	110
506	Role of elongin-binding domain of von Hippel Lindau gene product on HuR-mediated VPF/VEGF mRNA stability in renal cell carcinoma. <b>2005</b> , 24, 7850-8	44
505	Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. <b>2005</b> , 24, 7673-85	284
504	Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain. <b>2005</b> , 272, 6120-30	43
503	E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation. <b>2005</b> , 6, 429-41	182
502	A novel candidate region linked to development of both pheochromocytoma and head/neck paraganglioma. <b>2005</b> , 42, 260-8	25
501	Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. <b>2005</b> , 89, 193-201	114
500	Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. <b>2005</b> , 4, 13-6	45
499	The BTB Domain Zinc Finger Proteins. <b>2005</b> , 134-150	2

498	The SCF Ubiquitin E3 Ligase. <b>2005</b> , 135-155	
497	The Structural Biology of Ubiquitin-Protein Ligases. <b>2005</b> , 156-189	
496	ASB2 is an Elongin BC-interacting protein that can assemble with Cullin 5 and Rbx1 to reconstitute an E3 ubiquitin ligase complex. <b>2005</b> , 280, 5468-74	59
495	Ankyrin repeat and SOCS box 3 (ASB3) mediates ubiquitination and degradation of tumor necrosis factor receptor II. <b>2005</b> , 25, 4716-26	54
494	Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. <b>2005</b> , 102, 11444-9	160
493	Spinal hemangioblastoma containing metastatic renal cell carcinoma in von Hippel-Lindau disease. Case report and review of the literature. <b>2005</b> , 3, 495-500	31
492	Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL-hypoxia-inducible transcription factor-1alpha complex. <b>2005</b> , 280, 7985-96	35
491	BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. <b>2005</b> , 25, 162-71	551
490	Cullins 3a and 3b assemble with members of the broad complex/tramtrack/bric-a-brac (BTB) protein family to form essential ubiquitin-protein ligases (E3s) in Arabidopsis. <b>2005</b> , 280, 18810-21	119
489	Arabidopsis has two redundant Cullin3 proteins that are essential for embryo development and that interact with RBX1 and BTB proteins to form multisubunit E3 ubiquitin ligase complexes in vivo. <b>2005</b> , 17, 1180-95	124
488	Recruiting substrates to cullin 4-dependent ubiquitin ligases by DDB1. <b>2005</b> , 4, 27-9	13
487	Advanced genetic strategies for recombinant protein expression in Escherichia coli. <b>2005</b> , 115, 113-28	649
486	Proteasome-associated proteins: regulation of a proteolytic machine. <b>2005</b> , 386, 725-37	136
485	Prediction of multimolecular assemblies by multiple docking. <b>2005</b> , 349, 435-47	74
484	Structural basis for recruitment of Ubc12 by an E2 binding domain in NEDD8's E1. <b>2005</b> , 17, 341-50	140
483	The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. <b>2005</b> , 338, 627-38	175
482	Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. <b>2005</b> , 123, 1093-106	180
481	The pST44 polycistronic expression system for producing protein complexes in Escherichia coli. <b>2005</b> , 40, 385-95	117



480	The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. <b>2005</b> , 16, 564-74	55
479	Zinc Finger Proteins. <b>2005</b> ,	17
478	Proline hydroxylation and gene expression. <b>2005</b> , 74, 115-28	344
477	Sequence and structural analysis of BTB domain proteins. <b>2005</b> , 6, R82	466
476	Ubiquitin pathway in VHL cancer syndrome. <b>2006</b> , 8, 623-9	49
475	Structure of SAP18: a ubiquitin fold in histone deacetylase complex assembly. <i>Biochemistry</i> , <b>2006</b> , 45, 11974-82	3.2 9
474	The general transcription machinery and general cofactors. <b>2006</b> , 41, 105-78	600
473	Negative regulation of growth hormone receptor signaling. <b>2006</b> , 20, 241-53	154
472	Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. <b>2006</b> , 76, 217-57	191
471	A recombinant transducer-effector system: in vitro study of G inhibitory protein (G-alpha-i1) direct activators. <b>2006</b> , 453, 151-60	2
470	p53 stabilization and transactivation by a von Hippel-Lindau protein. <b>2006</b> , 22, 395-405	197
469	Coexpression of the subunits of T7 DNA polymerase from an artificial operon allows one-step purification of active gp5/Trx complex. <b>2006</b> , 47, 264-72	5
468	Renal Carcinoma and von Hippel-Lindau Disease. <b>2006</b> ,	
467	A novel mutation in the von Hippel-Lindau tumor suppressor gene identified in a Japanese family with pheochromocytoma and hepatic hemangioma. <b>2006</b> , 45, 265-9	4
466	The N131S mutation in the von Hippel-Lindau gene in a Japanese family with pheochromocytoma and hemangioblastomas. <b>2006</b> , 53, 819-27	2
465	Co-expression of protein complexes in prokaryotic and eukaryotic hosts: experimental procedures, database tracking and case studies. <b>2006</b> , 62, 1232-42	94
464	Drug discovery in the ubiquitin-proteasome system. <b>2006</b> , 5, 596-613	468
463	Lysine activation and functional analysis of E2-mediated conjugation in the SUMO pathway. <b>2006</b> , 13, 491-9	146

462	Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. <b>2006</b> , 13, 131-40	46
461	Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. <b>2006</b> , 13, 242-52	32
460	Ubiquitination-mediated protein degradation and modification: an emerging theme in plant-microbe interactions. <b>2006</b> , 16, 413-26	132
459	Structural and functional insights into the B30.2/SPRY domain. <b>2006</b> , 25, 1353-63	126
458	Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. <b>2006</b> , 25, 370-7	62
457	Homotypic association between tumour-associated VHL proteins leads to the restoration of HIF pathway. <b>2006</b> , 25, 3079-83	15
456	Mechanisms of Angiogenesis in Brain Tumors and their Translation into Therapeutic Anti-tumor Strategies. <b>2006</b> , 219-235	
455	Germline mutation of von Hippel-Lindau (VHL) gene 695 G>A (R161Q) in a patient with a peculiar phenotype with type 2C VHL syndrome. <b>2006</b> , 1073, 198-202	4
454	Interaction between Mnk2 and CBC(VHL) ubiquitin ligase E3 complex. <b>2006</b> , 49, 265-73	2
453	pVHL's kryptonite: E2-EPF UCP. <b>2006</b> , 10, 95-7	8
452	Born to bind: the BTB protein-protein interaction domain. <b>2006</b> , 28, 1194-202	176
451	The von Hippel-Lindau (VHL) germline mutation V84L manifests as early-onset bilateral pheochromocytoma. <b>2006</b> , 140, 685-90	18
450	Translational control of gene expression during hypoxia. <b>2006</b> , 5, 749-55	116
449	Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?. <b>2006</b> , 91, 2851-8	113
448	Molecular biology of renal cell cancer and the identification of therapeutic targets. <b>2006</b> , 24, 5593-600	50
447	Role of hypoxia-inducible factor-1alpha as a cancer therapy target. <b>2006</b> , 13 Suppl 1, S61-75	99
446	Cullin3 is a KLHL10-interacting protein preferentially expressed during late spermiogenesis. <b>2006</b> , 74, 102-8	47
445	Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. <b>2006</b> , 26, 5784-96	70

444	Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. <b>2006</b> , 103, 7637-42	129
443	Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. <b>2006</b> , 281, 13612-13619	91
442	Von Hippel-Lindau disease and endocrine tumour susceptibility. <b>2006</b> , 13, 415-25	61
441	Degrade to create: developmental requirements for ubiquitin-mediated proteolysis during early <i>C. elegans</i> embryogenesis. <b>2006</b> , 133, 773-84	62
440	pVHL function is essential for endothelial extracellular matrix deposition. <b>2006</b> , 26, 2519-30	76
439	Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. <b>2006</b> , 103, 105-10	240
438	Constitutive and UV-induced fibronectin degradation is a ubiquitination-dependent process controlled by beta-TrCP. <b>2006</b> , 281, 23060-5	17
437	DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. <b>2006</b> , 20, 2949-54	253
436	Adenovirus E4orf6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53. <b>2007</b> , 21, 1742-50	42
435	JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism. <b>2007</b> , 293, F1836-46	20
434	A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein. <b>2007</b> , 35, e142	10
433	RACK1 vs. HSP90: competition for HIF-1 alpha degradation vs. stabilization. <b>2007</b> , 6, 656-9	109
432	Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase. <b>2007</b> , 282, 15652-66	106
431	EGLN3 prolyl hydroxylase regulates skeletal muscle differentiation and myogenin protein stability. <b>2007</b> , 282, 12410-8	59
430	Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. <b>2007</b> , 27, 5381-92	89
429	The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells. <b>2007</b> ,	1
428	Viral control of the SUMO pathway: Gam1, a model system. <b>2007</b> , 35, 1419-21	12
427	SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. <b>2007</b> , 131, 584-95	466

426	A CUL-2 ubiquitin ligase containing three FEM proteins degrades TRA-1 to regulate <i>C. elegans</i> sex determination. <b>2007</b> , 13, 127-39	107
425	Testis-specific expression and genomic multiplicity of the rat Rtdpoz genes that encode bipartite TRAF- and POZ/BTB-domain proteins. <b>2007</b> , 387, 141-9	4
424	Hypoxia-inducible factors: crosstalk between their protein stability and protein degradation. <b>2007</b> , 257, 145-56	21
423	RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. <b>2007</b> , 25, 207-17	382
422	Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. <b>2007</b> , 5, 617-26	27
421	Molecular Pathology in Clinical Practice. <b>2007</b> ,	3
420	Von Hippel-Lindau disease. <b>2007</b> , 2, 145-73	247
419	[Molecular biology of the clear cell renal cell carcinoma: principles for a selective treatment]. <b>2007</b> , 31, 233-43	2
418	A patient with bilateral pheochromocytoma as part of a Von Hippel-Lindau (VHL) syndrome type 2C. <b>2007</b> , 5, 112	8
417	Small but versatile: the extraordinary functional and structural diversity of the beta-grasp fold. <b>2007</b> , 2, 18	110
416	Genotype-phenotype correlations in von Hippel-Lindau disease. <i>Human Mutation</i> , <b>2007</b> , 28, 143-9	4-7 174
415	VHL protein alterations in sporadic renal cell carcinoma. <b>2007</b> , 19, 784-9	5
414	Role of the ubiquitin proteasome system in renal cell carcinoma. <b>2007</b> , 8 Suppl 1, S4	16
413	HIF-2alpha downregulation in the absence of functional VHL is not sufficient for renal cell differentiation. <b>2007</b> , 7, 13	15
412	The <i>Caenorhabditis elegans</i> cell-cycle regulator ZYG-11 defines a conserved family of CUL-2 complex components. <b>2007</b> , 8, 279-86	40
411	Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. <b>2007</b> , 87, 1252-64	38
410	Ternary complex formation of pVHL, elongin B and elongin C visualized in living cells by a fluorescence resonance energy transfer-fluorescence lifetime imaging microscopy technique. <b>2007</b> , 274, 5567-75	8
409	The adenovirus E4orf6 E3 ubiquitin ligase complex assembles in a novel fashion. <b>2007</b> , 364, 36-44	34

408	Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. <b>2007</b> , 15, 1493-504	99
407	Ser80Ile mutation and a concurrent Pro25Leu variant of the VHL gene in an extended Hungarian von Hippel-Lindau family. <b>2008</b> , 9, 29	10
406	Recombinant amyloid beta-peptide production by coexpression with an affibody ligand. <b>2008</b> , 8, 82	32
405	A yeast three-hybrid system that reconstitutes mammalian hypoxia inducible factor regulatory machinery. <b>2008</b> , 9, 18	6
404	The von Hippel-Lindau gene: turning discovery into therapy. <b>2008</b> , 113, 1768-78	35
403	The many faces of the SOCS box. <b>2008</b> , 19, 371-81	136
402	Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. <b>2008</b> , 224, 265-83	132
401	NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHL. <b>2008</b> , 9, 486-91	35
400	The impact of O <sub>2</sub> availability on human cancer. <b>2008</b> , 8, 967-75	983
399	The VHL tumor suppressor and HIF: insights from genetic studies in mice. <b>2008</b> , 15, 650-9	107
398	The Genetics and Molecular Biology of Neural Tumors. <b>2008</b> ,	6
397	The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase. <b>2008</b> , 381, 928-40	83
396	Ligand binding mode of GABAA receptor-associated protein. <b>2008</b> , 381, 1320-31	38
395	Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. <b>2008</b> , 82, 8656-63	94
394	Characterization of Cullin-box sequences that direct recruitment of Cul2-Rbx1 and Cul5-Rbx2 modules to Elongin BC-based ubiquitin ligases. <b>2008</b> , 283, 8005-13	116
393	Nur77 upregulates HIF-alpha by inhibiting pVHL-mediated degradation. <b>2008</b> , 40, 71-83	29
392	Hypoxia-mediated Na-K-ATPase degradation requires von Hippel Lindau protein. <b>2008</b> , 22, 1335-42	34
391	Human immunodeficiency virus type 1 Vpr-binding protein VprBP, a WD40 protein associated with the DDB1-CUL4 E3 ubiquitin ligase, is essential for DNA replication and embryonic development. <b>2008</b> , 28, 5621-33	58

390	Classification, expression pattern, and E3 ligase activity assay of rice U-box-containing proteins. <b>2008</b> , 1, 800-15	93
389	Characterization of Arabidopsis and rice DWD proteins and their roles as substrate receptors for CUL4-RING E3 ubiquitin ligases. <b>2008</b> , 20, 152-67	182
388	Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design. <b>2008</b> , 105, 901-6	74
387	Three-dimensional high-resolution diffusion tensor imaging and tractography of the developing rabbit brain. <b>2008</b> , 30, 262-75	32
386	Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. <b>2008</b> , 8, 779-90	41
385	Itch <sup>-/-</sup> alphabeta and gammadelta T cells independently contribute to autoimmunity in Itchy mice. <b>2008</b> , 111, 4273-7282	38
384	Crystallization and preliminary X-ray analysis of the splice variant of human ankyrin repeat and suppressor of cytokine signaling box protein 9 (hASB9-2). <b>2008</b> , 15, 647-9	2
383	Ocular von Hippel-Lindau disease: clinical update and emerging treatments. <b>2008</b> , 19, 213-7	47
382	VHL type 2B mutations retain VBC complex form and function. <b>2008</b> , 3, e3801	23
381	Genetic counseling in renal masses. <b>2008</b> , 720840	
380	U19/Eaf2 binds to and stabilizes von hippel-lindau protein. <b>2009</b> , 69, 2599-606	28
379	Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. <b>2009</b> , 106, 20330-5	97
378	Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. <b>2009</b> , 83, 9682-93	95
377	VHL frameshift mutation as target of nonsense-mediated mRNA decay in <i>Drosophila melanogaster</i> and human HEK293 cell line. <b>2009</b> , 2009, 860761	7
376	VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL. <b>2009</b> , 284, 10514-22	16
375	Renal Cell Carcinoma. <b>2009</b> ,	3
374	Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas. <b>2009</b> , 161, 495-502	14
373	The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. <b>2009</b> , 76, 939-45	78

372	APOBEC proteins and intrinsic resistance to HIV-1 infection. <b>2009</b> , 364, 675-87	207
371	Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes. <b>2009</b> , 9, 229	17
370	Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network. <b>2009</b> , 583, 3704-10	19
369	Oxygen-independent degradation of HIF-alpha via bioengineered VHL tumour suppressor complex. <b>2009</b> , 1, 66-78	15
368	Mutation screening of VHL gene in a family with malignant bilateral pheochromocytoma: from isolated familial pheochromocytoma to von Hippel-Lindau disease. <b>2009</b> , 8, 465-71	16
367	Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis. <b>2009</b> , 77, 84-96	50
366	Structure of the human Nac1 POZ domain. <b>2009</b> , 65, 445-9	16
365	Crystal structure of the Bach1 BTB domain and its regulation of homodimerization. <b>2009</b> , 14, 167-78	16
364	Generating specificity and diversity in the transcriptional response to hypoxia. <b>2009</b> , 10, 821-32	270
363	VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. <b>2009</b> , 28, 1694-705	32
362	The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL). <b>2009</b> , 28, 1864-74	25
361	Structural framework of the GABARAP-calreticulin interface--implications for substrate binding to endoplasmic reticulum chaperones. <b>2009</b> , 276, 1140-52	35
360	Regulation of DNA topoisomerase IIalpha stability by the ECV ubiquitin ligase complex. <b>2009</b> , 389, 5-9	4
359	The SOCS box encodes a hierarchy of affinities for Cullin5: implications for ubiquitin ligase formation and cytokine signalling suppression. <b>2009</b> , 387, 162-74	99
358	Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. <b>2009</b> , 36, 39-50	315
357	[Hereditary renal cancer]. <b>2009</b> , 33, 127-33	4
356	Crystallization and preliminary X-ray analysis of the splice variant of human ankyrin repeat and suppressor of cytokine signaling box protein 9 (hASB9-2). <b>2009</b> , 16, 333-5	5
355	The VHL tumor suppressor: master regulator of HIF. <b>2009</b> , 15, 3895-903	84

354	Neuronal differentiation of neural progenitor cells by intracellular delivery of synthetic oligopeptide derived from Von Hippel-Lindau protein. <b>2009</b> , 16, 1291-6		11
353	Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure. <b>2010</b> , 17, 988-98		17
352	Von Hippel Lindau syndrome. <b>2010</b> , 685, 228-49		32
351	Structural assembly of cullin-RING ubiquitin ligase complexes. <b>2010</b> , 20, 714-21		166
350	Clinical and molecular features of familial and sporadic cases of von Hippel-Lindau disease from Mexico. <b>2010</b> , 38, 277-83		4
349	Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. <i>Human Mutation</i> , <b>2010</b> , 31, 41-51	4-7	286
348	Genetic analysis of von Hippel-Lindau disease. <i>Human Mutation</i> , <b>2010</b> , 31, 521-37	4-7	186
347	von Hippel-Lindau E3 domain-luciferase fusion protein as a bioluminescent hydroxyproline sensor for a hypoxia-inducible factor prolyl hydroxylase assay. <b>2010</b> , 407, 220-5		3
346	PIASy stimulates HIF1 $\beta$ SUMOylation and negatively regulates HIF1 $\alpha$ activity in response to hypoxia. <b>2010</b> , 29, 5568-78		47
345	Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. <b>2010</b> , 5, e9720		62
344	Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. <b>2010</b> , 4, 187-97		1
343	Mammalian SWI/SNF--a subunit BAF250/ARID1 is an E3 ubiquitin ligase that targets histone H2B. <b>2010</b> , 30, 1673-88		84
342	DWA1 and DWA2, two Arabidopsis DWD protein components of CUL4-based E3 ligases, act together as negative regulators in ABA signal transduction. <b>2010</b> , 22, 1716-32		178
341	Structural basis of dimerization-dependent ubiquitination by the SCF(Fbx4) ubiquitin ligase. <b>2010</b> , 285, 13896-906		27
340	The CRL2LRR-1 ubiquitin ligase regulates cell cycle progression during <i>C. elegans</i> development. <b>2010</b> , 137, 3857-66		26
339	Neuroendocrine tumors and tumor syndromes in childhood. <b>2010</b> , 13, 427-41		8
338	Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype. <b>2010</b> , 51, 4464-70		27
337	Experimental and computational studies indicate specific binding of pVHL protein to Aurora-A kinase. <b>2010</b> , 114, 1486-97		5



336	Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. <b>2010</b> , 84, 7135-9	39
335	Molecular diagnosis and therapy of kidney cancer. <b>2010</b> , 61, 329-43	135
334	Hypoxic regulation of erythropoiesis and iron metabolism. <b>2010</b> , 299, F1-13	208
333	Chemical basis for the selectivity of the von Hippel Lindau tumor suppressor pVHL for prolyl-hydroxylated HIF-1alpha. <i>Biochemistry</i> , <b>2010</b> , 49, 6936-44	3.2 14
332	The diversity of ubiquitin recognition: hot spots and varied specificity. <b>2010</b> , 38, 627-35	125
331	Solution and electron microscopy characterization of lactococcal phage baseplates expressed in <i>Escherichia coli</i> . <b>2010</b> , 172, 75-84	33
330	The x-ray crystal structure of the first RNA recognition motif and site-directed mutagenesis suggest a possible HuR redox sensing mechanism. <b>2010</b> , 397, 1231-44	37
329	Action of the chaperonin GroEL/ES on a non-native substrate observed with single-molecule FRET. <b>2010</b> , 401, 553-63	16
328	Phosphorylation of the von Hippel-Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1alpha mediated transcription. <b>2010</b> , 42, 1729-35	30
327	Diseases of DNA Repair. <b>2010</b> ,	2
326	The cullin protein family. <b>2011</b> , 12, 220	302
325	. <b>2011</b> ,	9
324	Von Hippel-Lindau. <b>2011</b> ,	
323	Familial Catecholamine-Secreting Tumors - Three Distinct Families with Hereditary Pheochromocytoma. <b>2011</b> ,	
322	The SOCS2 ubiquitin ligase complex regulates growth hormone receptor levels. <b>2011</b> , 6, e25358	52
321	Making Order in the Intrinsically Disordered Regions of HIV-1 Vif Protein. <b>2011</b> , 201-221	1
320	Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma. <b>2011</b> , 79, 539-45	4
319	Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor. <b>2011</b> , 30, 21-31	21

318	von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage. <b>2011</b> , 30, 3127-38	22
317	von Hippel-Lindau disease: a clinical and scientific review. <b>2011</b> , 19, 617-23	439
316	Coronin7 forms a novel E3 ubiquitin ligase complex to promote the degradation of the anti-proliferative protein Tob. <b>2011</b> , 585, 65-70	1
315	The cullin-RING ubiquitin-protein ligases. <b>2011</b> , 62, 299-334	326
314	Regulation of hypoxia-inducible factor 1 and the loss of the cellular response to hypoxia in diabetes. <b>2011</b> , 54, 1946-56	102
313	Impact of genetics on the diagnosis and treatment of renal cancer. <b>2011</b> , 12, 47-55	17
312	Twists and turns in ubiquitin-like protein conjugation cascades. <b>2011</b> , 20, 1941-54	35
311	Genotype-phenotype correlations of pheochromocytoma in two large von Hippel-Lindau (VHL) type 2A kindreds with different missense mutations. <b>2011</b> , 155A, 168-73	17
310	Perturbation of cullin deneddylation via conditional Csn8 ablation impairs the ubiquitin-proteasome system and causes cardiomyocyte necrosis and dilated cardiomyopathy in mice. <b>2011</b> , 108, 40-50	77
309	Cullin 4B protein ubiquitin ligase targets peroxiredoxin III for degradation. <b>2011</b> , 286, 32344-54	41
308	Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas. <b>2011</b> , 25, 1311-25	14
307	Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function. <b>2011</b> , 124, 2132-42	12
306	Studies on Renal Disorders. <b>2011</b> ,	3
305	A direct way of redox sensing. <b>2011</b> , 8, 18-23	9
304	Identification of a Cullin5-ElonginB-ElonginC E3 complex in degradation of feline immunodeficiency virus Vif-mediated feline APOBEC3 proteins. <b>2011</b> , 85, 12482-91	26
303	Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. <b>2011</b> , 17, 845-53	60
302	Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA. <i>Molecular Cancer Research</i> , <b>2012</b> , 10, 108-20	6.6 21
301	Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms. <b>2012</b> , 31, 2247-57	37

300	Regenerative Biology of the Spine and Spinal Cord. <b>2012,</b>	
299	Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma. <b>2012, 41, 1229-40</b>	10
298	The ubiquitin-proteasome system: central modifier of plant signalling. <b>2012, 196, 13-28</b>	213
297	Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. <b>2012, 45, 233-43</b>	58
296	Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent. <b>2012, 20, 4590-7</b>	31
295	Identification of 3 novel VHL germ-line mutations in Danish VHL patients. <b>2012, 13, 54</b>	13
294	Structural insights into functional modes of proteins involved in ubiquitin family pathways. <b>2012, 832, 547-76</b>	9
293	Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma. <b>2012, 36, 99-103</b>	3
292	Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy. <b>2012, 6, 267-75</b>	46
291	Malignancies of the spinal cord. <b>2012, 760, 101-13</b>	7
290	The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer. <b>2012, 2, 35</b>	32
289	The natural history of ubiquitin and ubiquitin-related domains. <b>2012, 17, 1433-60</b>	36
288	The SOCS box-adapting proteins for ubiquitination and proteasomal degradation. <b>2012, 64, 316-23</b>	75
287	Hypoxia inducible factor-1: its potential role in cerebral ischemia. <b>2012, 32, 491-507</b>	93
286	Crystal structure of Human ASB9-2 and substrate-recognition of CKB. <b>2012, 31, 275-84</b>	11
285	[Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma]. <b>2012, 36, 99-103</b>	5
284	Systemic VHL gene functions and the VHL disease. <b>2012, 586, 1562-9</b>	56
283	Functional diversification of the Tubby-like protein gene families (TULPs) during eukaryotic evolution. <b>2012, 1, 2-8</b>	7

282	A c.464T>a mutation in VHL gene in a Chinese family with VHL syndrome. <b>2013</b> , 111, 313-8	6
281	Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis. <b>2013</b> , 20, 923-30	9
280	Regulation of erythropoiesis by hypoxia-inducible factors. <b>2013</b> , 27, 41-53	371
279	The Phakomatoses. <b>2013</b> , 1-45	1
278	von Hippel-Lindau syndrome. <b>2013</b> , 41, 30-49	37
277	Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-1 binding to Vif. <b>2013</b> , 10, 94	22
276	Structural basis of intersubunit recognition in elongin BC-cullin 5-SOCS box ubiquitin-protein ligase complexes. <b>2013</b> , 69, 1587-97	26
275	Simulation of the mutation F76del on the von Hippel-Lindau tumor suppressor protein: mechanism of the disease and implications for drug development. <b>2013</b> , 81, 349-63	5
274	Von Hippel-Lindau: how a rare disease illuminates cancer biology. <b>2013</b> , 23, 26-37	77
273	Molecular architecture of the ankyrin SOCS box family of Cul5-dependent E3 ubiquitin ligases. <b>2013</b> , 425, 3166-77	30
272	A deletion mutation of the VHL gene associated with a patient with sporadic von Hippel-Lindau disease. <b>2013</b> , 20, 842-7	7
271	A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytoma. <b>2013</b> , 78, 391-7	5
270	Three novel germ-line VHL mutations in Hungarian von Hippel-Lindau patients, including a nonsense mutation in a fifteen-year-old boy with renal cell carcinoma. <b>2013</b> , 14, 3	2
269	Functional significance of erythropoietin in renal cell carcinoma. <b>2013</b> , 13, 14	29
268	Familial Renal Cell Carcinoma. <b>2013</b> , 43-52	
267	Integrated molecular analysis of clear-cell renal cell carcinoma. <b>2013</b> , 45, 860-7	723
266	A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts. <b>2013</b> , 12, 111-7	3
265	p.N78S and p.R161Q germline mutations of the VHL gene are present in von Hippel-Lindau syndrome in two pedigrees. <b>2013</b> , 8, 799-805	4

264	DCNL1 functions as a substrate sensor and activator of cullin 2-RING ligase. <b>2013</b> , 33, 1621-31	13
263	Von hippel-lindau disease: a genetic and clinical review. <b>2013</b> , 28, 377-86	41
262	Crystal structure of the gamma-2 herpesvirus LANA DNA binding domain identifies charged surface residues which impact viral latency. <b>2013</b> , 9, e1003673	25
261	Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response. <b>2013</b> , 105, 1355-64	10
260	Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. <b>2013</b> , 288, 7803-7814	169
259	VHL gene alterations in Italian patients with isolated renal cell carcinomas. <b>2013</b> , 28, 208-15	2
258	von Hippel-Lindau (VHL) Protein. <b>2013</b> , 570-571	
257	Identification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome. <b>2014</b> , 13, 10177-83	2
256	Sunitinib resistance in renal cell carcinoma. <b>2014</b> , 1, 1-11	34
255	Role of cullin-elonginB-elonginC E3 complex in bovine immunodeficiency virus and maedi-visna virus Vif-mediated degradation of host A3Z2-Z3 proteins. <b>2014</b> , 11, 77	13
254	Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel-Lindau (VHL) disease. <b>2014</b> , 59, 488-93	10
253	Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. <b>2014</b> , 74, 6554-64	18
252	Molecular dissection of the VHL gene in solitary capillary hemangioblastoma of the central nervous system. <b>2014</b> , 73, 50-8	10
251	An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 5976-88	5.6 19
250	Structural basis for hijacking CBF-1 and CUL5 E3 ligase complex by HIV-1 Vif. <b>2014</b> , 505, 229-33	153
249	Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. <b>2014</b> , 14, 108-19	354
248	Von hippel-lindau disease associated pulmonary carcinoid with cranial metastasis. <b>2014</b> , 99, 2633-6	6
247	Hereditary kidney cancer syndromes. <b>2014</b> , 21, 81-90	93

246	Molecular genetics of clear-cell renal cell carcinoma. <b>2014</b> , 32, 1968-76	213
245	Encyclopedia of Cancer. <b>2014</b> , 1461-1466	
244	Inhibition of elongin C promotes longevity and protein homeostasis via HIF-1 in <i>C. elegans</i> . <b>2015</b> , 14, 995-1002	16
243	Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 26706-20	6.3 46
242	E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis. <b>2015</b> , 15, 800	11
241	Posttranscriptional adaptations of the vascular endothelium to hypoxia. <b>2015</b> , 22, 243-51	
240	Metastatic pheochromocytoma in a 23-year-old woman with an unclassified variant in the von Hippel Lindau disease gene: how can the pathogenicity of this variant be determined?. <b>2015</b> , 83, 15-9	3
239	Clinical and genetic investigation of a multi-generational Chinese family afflicted with Von Hippel-Lindau disease. <b>2015</b> , 128, 32-8	3
238	Serendipitous SAD Solution for DMSO-Soaked SOCS2-ElonginC-ElonginB Crystals Using Covalently Incorporated Dimethylarsenic: Insights into Substrate Receptor Conformational Flexibility in Cullin RING Ligases. <b>2015</b> , 10, e0131218	12
237	Implications of Von Hippel-Lindau Syndrome and Renal Cell Carcinoma. <b>2015</b> , 2, 163-173	13
236	Structural Basis for Modulation of Quality Control Fate in a Marginally Stable Protein. <b>2015</b> , 23, 1169-78	6
235	Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex. <b>2015</b> , 23, 441-449	40
234	E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1 $\alpha$ to Maintain Regulatory T Cell Stability and Suppressive Capacity. <b>2015</b> , 42, 1062-74	132
233	Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation. <b>2015</b> , 467, 365-86	130
232	VHL and HIF in Clear Cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications. <b>2015</b> , 57-110	
231	Genotype-phenotype analysis of von Hippel-Lindau syndrome in fifteen Indian families. <b>2015</b> , 14, 585-94	11
230	VHL: Cullin-g the hypoxic response. <b>2015</b> , 23, 435-436	4
229	Intramedullary Spinal Cord Tumors: Part I-Epidemiology, Pathophysiology, and Diagnosis. <b>2015</b> , 5, 425-35	104

228	A Novel von Hippel Lindau Gene Intronic Variant and Its Reclassification from VUS to Pathogenic: the Impact on a Large Family. <b>2015</b> , 24, 882-9	8
227	Structural basis of Keap1 interactions with Nrf2. <b>2015</b> , 88, 101-107	253
226	Renal Cell Carcinoma. <b>2015</b> ,	
225	VHL, the story of a tumour suppressor gene. <b>2015</b> , 15, 55-64	399
224	β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma. <b>2015</b> , 26, 553-64	47
223	SOCS2: physiological and pathological functions. <b>2016</b> , 8, 189-204	40
222	Structured assessment and followup for patients with hereditary kidney tumour syndromes. <b>2016</b> , 10, E214-E222	7
221	Molecular Characterization of a Novel Germline VHL Mutation by Extensive In Silico Analysis in an Indian Family with Von Hippel-Lindau Disease. <b>2016</b> , 2016, 9872594	1
220	TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer. <b>2016</b> , 35, 359-65	7
219	Germline mutations in the VHL gene associated with 3 different renal lesions in a Chinese von Hippel-Lindau disease family. <b>2016</b> , 17, 599-603	3
218	Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. <b>2016</b> , 34, 2172-81	95
217	Von Hippel-Lindau Disease. <b>2016</b> , 5, 116-23	33
216	The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions. <b>2016</b> , 11, 7	35
215	EPOP Functionally Links Elongin and Polycomb in Pluripotent Stem Cells. <b>2016</b> , 64, 645-658	81
214	Potent and selective chemical probe of hypoxic signalling downstream of HIF-1α hydroxylation via VHL inhibition. <b>2016</b> , 7, 13312	110
213	Clinical and molecular characteristics of East Asian patients with von Hippel-Lindau syndrome. <b>2016</b> , 35, 79	3
212	Golgi Associated HIF1a Serves as a Reserve in Melanoma Cells. <b>2016</b> , 117, 853-9	2
211	Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL. <b>2017</b> , 36, 3450-3463	29

210	Neuroregeneration of Induced Pluripotent Stem Cells in Polyacrylamide-Chitosan Inverted Colloidal Crystal Scaffolds with Poly(lactide-co-glycolide) Nanoparticles and Transactivator of Transcription von Hippel-Lindau Peptide. <b>2017</b> , 23, 263-274	6
209	Genomes, structural biology and drug discovery: combating the impacts of mutations in genetic disease and antibiotic resistance. <b>2017</b> , 45, 303-311	26
208	Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. <b>2017</b> , 23, e68-e75	127
207	RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbistatin emergency program. <b>2017</b> , 3, 17023	14
206	Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex. <b>2017</b> , 25, 901-911.e3	56
205	Rootletin prevents Cep68 from VHL-mediated proteasomal degradation to maintain centrosome cohesion. <b>2017</b> , 1864, 645-654	11
204	Structural basis of PROTAC cooperative recognition for selective protein degradation. <b>2017</b> , 13, 514-521	460
203	Traveling Rocky Roads: The Consequences of Transcription-Blocking DNA Lesions on RNA Polymerase II. <b>2017</b> , 429, 3146-3155	14
202	Molecular Genetics of Pheochromocytoma and Paraganglioma. <b>2017</b> , 15-45	
201	Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. <b>2017</b> , 8, 830	117
200	Phosphorylation and Ubiquitination Regulate Protein Phosphatase 5 Activity and Its Prosurvival Role in Kidney Cancer. <b>2017</b> , 21, 1883-1895	26
199	An Elongin-Cullin-SOCS Box Complex Regulates Stress-Induced Serotonergic Neuromodulation. <b>2017</b> , 21, 3089-3101	7
198	Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics. <b>2017</b> , 5, 11-20	17
197	The molecular basis of JAK/STAT inhibition by SOCS1. <b>2018</b> , 9, 1558	141
196	Integrating Cross-Linking Experiments with Ab Initio Protein-Protein Docking. <b>2018</b> , 430, 1814-1828	12
195	In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. <b>2018</b> , 103, 1631-1638	9
194	Genotype and phenotype correlation in von Hippel-Lindau disease based on alteration of the HIF-1 $\alpha$ binding site in VHL protein. <b>2018</b> , 20, 1266-1273	20
193	2-Oxoglutarate regulates binding of hydroxylated hypoxia-inducible factor to prolyl hydroxylase domain 2. <b>2018</b> , 54, 3130-3133	23



192	Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine (VH298). <b>2018</b> , 61, 599-618	67
191	The HIF and other quandaries in VHL disease. <b>2018</b> , 37, 139-147	49
190	Extraneuraxial Hemangioblastoma: Clinicopathologic Features and Review of the Literature. <b>2018</b> , 25, 197-215	18
189	Renal Cell Carcinoma: Molecular Aspects. <b>2018</b> , 33, 246-254	20
188	Genome-wide identification and expression analysis of the BTB domain-containing protein gene family in tomato. <b>2018</b> , 40, 1-15	19
187	Novel Class of Viral Ankyrin Proteins Targeting the Host E3 Ubiquitin Ligase Cullin-2. <b>2018</b> , 92,	12
186	The molecular details of cytokine signaling via the JAK/STAT pathway. <b>2018</b> , 27, 1984-2009	194
185	HIF-2 $\beta$ -VHL complex reveals broad genotype-phenotype correlations in HIF-2 $\beta$ -driven disease. <b>2018</b> , 9, 3359	17
184	Circulating Tumor Cells for the Management of Renal Cell Carcinoma. <b>2018</b> , 8,	8
183	CRL4 targets Elongin C for ubiquitination and degradation to modulate CRL5 signaling. <b>2018</b> , 37,	6
182	3-Fluoro-4-hydroxyprolines: Synthesis, Conformational Analysis, and Stereoselective Recognition by the VHL E3 Ubiquitin Ligase for Targeted Protein Degradation. <b>2018</b> , 140, 9299-9313	64
181	Proline hydroxylation at different sites in hypoxia-inducible factor 1 $\alpha$ modulates its interactions with the von Hippel-Lindau tumor suppressor protein. <b>2018</b> , 20, 18756-18765	4
180	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. <i>Science</i> , <b>2018</b> , 361, 290-295	33-3 73
179	Von Hippel-Lindau disease and Sturge-Weber syndrome. <b>2018</b> , 148, 823-826	2
178	Identification of a new exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. <b>2018</b> , 132, 469-483	37
177	Adenoviral delivery of VHL suppresses bone sarcoma cell growth through inhibition of Wnt/ $\beta$ -catenin signaling. <b>2019</b> , 26, 83-93	8
176	The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel-Lindau Disease: A Retrospective Study of 32 Patients. <b>2019</b> , 9, 1122	5
175	Frequent Mutations of VHL Gene and the Clinical Phenotypes in the Largest Chinese Cohort With Von Hippel-Lindau Disease. <b>2019</b> , 10, 867	7

174	Oxygen sensing decoded: a Nobel concept in biology. <b>2019</b> , 22, 471-472	7
173	A Compendium of Genetic Modifiers of Mitochondrial Dysfunction Reveals Intra-organelle Buffering. <b>2019</b> , 179, 1222-1238.e17	47
172	The dark proteome of cancer: Intrinsic disorderedness and functionality of HIF-1 $\alpha$ along with its interacting proteins. <b>2019</b> , 166, 371-403	15
171	Proteomic analysis of flavokawain C-induced cell death in HCT 116 colon carcinoma cell line. <b>2019</b> , 853, 388-399	3
170	Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors. <b>2019</b> , 15, e1006478	12
169	Hereditary Cancer Syndromes: Risk Assessment and Genetic Counseling. <b>2019</b> , 1-27	
168	Protein misfolding in endoplasmic reticulum stress with applications to renal diseases. <b>2019</b> , 118, 217-247	1
167	von Hippel-Lindau Disease: an Update. <b>2019</b> , 7, 227-235	4
166	Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome. <b>2019</b> , 38, 1038-1049	4
165	Immune regulation by protein ubiquitination: roles of the E3 ligases VHL and Itch. <b>2019</b> , 10, 395-404	11
164	A Synthetic Oxygen Sensor for Plants Based on Animal Hypoxia Signaling. <b>2019</b> , 179, 986-1000	15
163	Structural basis for renal cancer by the dynamics of pVHL-dependent JADE1 stabilization and Ectenin regulation. <b>2019</b> , 145, 65-77	2
162	Bayesian Weighing of Electron Cryo-Microscopy Data for Integrative Structural Modeling. <b>2019</b> , 27, 175-188.e624	
161	Radiogenomics in renal cell carcinoma. <b>2019</b> , 44, 1990-1998	24
160	The air that we breathe: From 'Noble' discoveries of a general oxygen-sensing principle to its clinical use. <b>2020</b> , 228, e13416	0
159	Molecular biology and targeted therapy in metastatic renal cell carcinoma. <b>2020</b> , 13, 40-49	
158	A Cellular Mechanism to Detect and Alleviate Reductive Stress. <b>2020</b> , 183, 46-61.e21	32
157	Hypoxia-inducible factors not only regulate but also are myeloid-cell treatment targets. <b>2021</b> , 110, 61-75	2

156	Pituitary Metastatic Composite Tumors: A Case Report with Next-Generation Sequencing and Review of the Literature. <b>2020</b> , 2020, 5073236	0
155	Analysis of Multiplicity of Hypoxia-Inducible Factors in the Evolution of Fish (Osteichthyes: Nemacheilinae) Reveals Hypoxic Environments Adaptation to Tibetan Plateau. <b>2020</b> , 11, 433	5
154	The long form of pVHL is artifactually modified by serine protease inhibitor AEBSF. <b>2020</b> , 29, 1843-1850	1
153	Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors. <b>2020</b> , 39, 5228-5239	6
152	NRBP1-Containing CRL2/CRL4A Regulates Amyloid $\beta$ Production by Targeting BRI2 and BRI3 for Degradation. <b>2020</b> , 30, 3478-3491.e6	6
151	Oxygen sensing; a stunningly elegant molecular machinery highjacked in cancer. <b>2020</b> , 125, 205-210	2
150	VHL-RELATED NEUROENDOCRINE NEOPLASMS AND BEYOND: AN ISRAELI SPECIALIZED CENTER REAL-LIFE REPORT. <b>2020</b> ,	
149	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. <b>2020</b> , 38, 1146-1153	21
148	Ein Gespür für Sauerstoff: Entdeckung des molekularen Mechanismus der zellulären Sauerstoffregulation rückt die Hydroxylierung von Makromolekülen in den Blickpunkt. <b>2020</b> , 132, 3804-3809	
147	An Oxygen Sensation: Progress in Macromolecule Hydroxylation Triggered by the Elucidation of Cellular Oxygen Sensing. <b>2020</b> , 59, 3776-3780	3
146	Role of VHL-JAK-STAT signaling pathway in central nervous system hemangioblastoma associated with von Hippel-Lindau disease. <b>2020</b> , 148, 29-38	3
145	Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: a large retrospective study. <b>2020</b> , 57, 744-751	1
144	Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer. <b>2020</b> , 67, 34-42	5
143	E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. <b>2021</b> , 26, 484-502	48
142	Building ubiquitination machineries: E3 ligase multi-subunit assembly and substrate targeting by PROTACs and molecular glues. <b>2021</b> , 67, 110-119	16
141	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <b>2021</b> , 7, 381-389	7
140	A comprehensive phenotypic CRISPR-Cas9 screen of the ubiquitin pathway uncovers roles of ubiquitin ligases in mitosis. <b>2021</b> , 81, 1319-1336.e9	8
139	HIF Pathways in Clear Cell Renal Cancer.	1

138	Identification of an atypical interaction site in the BTB domain of the MYC-interacting zinc-finger protein 1. <b>2021</b> , 29, 1230-1240.e5	6
137	Cullin-RING Ubiquitin Ligase Regulatory Circuits: A Quarter Century Beyond the F-Box Hypothesis. <b>2021</b> , 90, 403-429	17
136	High nuclear expression of HIF1 $\alpha$ synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence. <b>2021</b> , 147, 2309-2322	0
135	An E3 ligase guide to the galaxy of small-molecule-induced protein degradation. <b>2021</b> , 28, 1000-1013	12
134	pVHL promotes lysosomal degradation of YAP in lung adenocarcinoma. <b>2021</b> , 83, 110002	0
133	A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer. <b>2021</b> , 39, 548-560	2
132	A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. <b>2021</b> , 13, eabj1578	10
131	Amyloidogenic Properties of Peptides Derived from the VHL Tumor Suppressor Protein. <b>2021</b> , 16, 3565-3568	
130	Analysis of potential genetic biomarkers and molecular mechanism of smoking-related postmenopausal osteoporosis using weighted gene co-expression network analysis and machine learning. <b>2021</b> , 16, e0257343	2
129	The von Hippel-Lindau Cullin-RING E3 ubiquitin ligase regulates APOBEC3 cytidine deaminases. <b>2021</b> , 237, 1-15	0
128	Relationship between visceral adipose tissue and genetic mutations (VHL and KDM5C) in clear cell renal cell carcinoma. <b>2021</b> , 126, 645-651	11
127	Molecular genetics of kidney cancer. <b>2003</b> , 116, 3-27	4
126	The pVHL-HIF-1 system. <b>2001</b> , 365-376	67
125	Structure and evolution of ubiquitin and ubiquitin-related domains. <b>2012</b> , 832, 15-63	33
124	Roles of SCF and VHL ubiquitin ligases in regulation of cell growth. <b>2002</b> , 29, 1-15	7
123	Natural substrates of the proteasome and their recognition by the ubiquitin system. <b>2002</b> , 268, 137-74	24
122	Structural Biology of CRL Ubiquitin Ligases. <b>2020</b> , 1217, 9-31	14
121	Spinal Axis Tumors: Incidence, Classification, and Diagnostic Imaging. <b>2005</b> , 476-484	2

120	Hematologic Aspects of Kidney Disease. <b>2012</b> , 2081-2121	1
119	Treatment of Advanced Renal Cell Carcinoma. <b>2012</b> , 1475-1491.e5	2
118	Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel-Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay. <b>2021</b> , 6, 680-695	5
117	Isolation and characterization of HRT1 using a genetic screen for mutants unable to degrade Gic2p in <i>Saccharomyces cerevisiae</i> . <b>2000</b> , 155, 1033-44	20
116	Bayesian weighing of electron cryo-microscopy data for integrative structural modeling.	3
115	The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. <b>2005</b> , 70, 159-66	49
114	The 2019 Nobel Prize honors fundamental discoveries in hypoxia response. <b>2020</b> , 130, 4-6	7
113	HIF hydroxylation and the mammalian oxygen-sensing pathway. <b>2003</b> , 111, 779-83	100
112	HIF hydroxylation and the mammalian oxygen-sensing pathway. <b>2003</b> , 111, 779-783	246
111	S-nitrosothiols signal hypoxia-mimetic vascular pathology. <b>2007</b> , 117, 2592-601	132
110	Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. <b>1999</b> , 104, 1583-91	75
109	William Kaelin, Peter Ratcliffe, and Gregg Semenza receive the 2016 Albert Lasker Basic Medical Research Award. <b>2016</b> , 126, 3628-3638	10
108	Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. <b>2010</b> , 5, e12636	42
107	P.Arg82Leu von Hippel-Lindau (VHL) gene mutation among three members of a family with familial bilateral pheochromocytoma in India: molecular analysis and in silico characterization. <b>2013</b> , 8, e61908	7
106	Structural insights into the folding defects of oncogenic pVHL lead to correction of its function in vitro. <b>2013</b> , 8, e66333	8
105	Computational and experimental characterization of dVHL establish a <i>Drosophila</i> model of VHL syndrome. <b>2014</b> , 9, e109864	1
104	USP9X destabilizes pVHL and promotes cell proliferation. <b>2016</b> , 7, 60519-60534	14
103	Molecular markers of paragangliomas/pheochromocytomas. <b>2017</b> , 8, 25756-25782	26

102	Genotype-phenotype correlations in Chinese von Hippel-Lindau disease patients. <b>2017</b> , 8, 38456-38465	18
101	Atlas on substrate recognition subunits of CRL2 E3 ligases. <b>2016</b> , 7, 46707-46716	13
100	Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the Mutation p.P81S (c.241C>T). <b>2017</b> , 18, 93-103	2
99	Advances in the structural understanding of Vif proteins. <b>2008</b> , 6, 91-9	39
98	Predicting Multi-Component Protein Assemblies Using an Ant Colony Approach. <b>2012</b> , 3, 19-31	2
97	Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future. <b>2009</b> , 25, 427-36	8
96	Von Hippel-Lindau Disease: The Importance of Retinal Hemangioblastomas in Diagnosis. <b>2017</b> , 47, 180-183	5
95	Molecular Epidemiology: Beyond Gene Discovery to Clinical Diagnostic Tools. <b>2001</b> , 307-316	
94	Familiales Nierenkarzinom. <b>2001</b> , 439-469	
93	The Transcription of Genes. <b>2001</b> , 1603-1667	
92	BTB/POZ Motif.	
91	VHL (von Hippel-Lindau) Protein.	
90	von Hippel-Lindau Disease. <b>2002</b> , 527-532	
89	Nierenzellkarzinome. <b>2002</b> , 257-289	
88	Elongins.	
87	Gene and Protein Expression and Regulation in the Central Nervous System. <b>2002</b> ,	
86	Negative Regulation of the JAK/STAT Signaling Pathway. <b>2003</b> , 431-440	
85	Surgery for Primary and Metastatic Tumors of the Spine. <b>2003</b> , 503-545	

84 Regulation of HIF-1 by Oxygen. **2003**, 47-64

2

83 Von Hippel-Lindau (VHL) Protein. **2004**, 416-418

82 Role of VHL in Mammalian Oxygen Sensing. **2004**, 5, 66-69

81 von Hippel-Lindau Disease. **2007**, 263-266

80 Regulation of Angiogenesis by von Hippel Lindau Protein and HIF2. **2008**, 181-191

79 Von Hippel-Lindau Disease. **2009**, 259-262

78 The Molecular Biology of Kidney Cancer and Its Clinical Translation into Treatment Strategies. **2009**, 79-97

77 Modulation of Protein Stability: Targeting the VHL Pathway. **2009**, 45-63

76 von Hippel-Lindau Disease. **2009**, 97-100

75 von Hippel-Lindau Tumor Suppressor, Hypoxia-Inducible Factor-1, and Tumor Vascularization. **2010**, 119-132

74 Renal Carcinoma and von Hippel-Lindau Disease.

73 Oxygen-Dependent Regulation of Erythropoiesis. **2011**, 437-463

72 Oxygen-Sensitive Transcription Factors and Hypoxia-Mediated Pulmonary Hypertension. **2011**, 713-723

71 Encyclopedia of Cancer. **2011**, 1217-1220

70 Biomarkers for Prognosis and Molecularly Targeted Therapy in Renal Cell Carcinoma. **2012**, 289-324

69 The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies. **2012**, 3-25

1

68 Encyclopedia of Cancer. **2015**, 1-3

67 Encyclopedia of Cancer. **2015**, 1490-1492

66	Von Hippel-Lindau Disease. <b>2016</b> , 365-368		
65	Renal Carcinoma and von Hippel-Lindau Disease. 1-7		
64	Integrating cross-linking experiments with ab initio protein-protein docking.		
63	Algorithmic Assessment of Missense Mutation Severity in the Von-Hippel Lindau Protein.		
62	Renal Cell Cancer. <b>2006</b> , 789-812		
61	Para- und autokrine Aspekte der Pathogenese des duktaalen Pankreaskarzinoms: Einfluss von Zytokinen und Wachstumsfaktoren. <b>2006</b> , 309-321		
60	Somatic Alterations in Prostate Cancer Progression. <b>2007</b> , 269-283		
59	Hemangioblastoma of the Central Nervous System. <b>2008</b> , 145-164		
58	von Hippel-Lindau Disease. <b>2008</b> , 151-159		
57	Algorithmic assessment of missense mutation severity in the Von-Hippel Lindau protein. <b>2020</b> , 15, e0234100	1	
56	Targeted genes and interacting proteins of hypoxia inducible factor-1. <b>2012</b> , 3, 165-78		130
55	The VHL Tumor Suppressor Gene: Insights into Oxygen Sensing and Cancer. <b>2017</b> , 128, 298-307		56
54	Intrabody Targeting HIF-1 $\alpha$ Mediates Transcriptional Downregulation of Target Genes Related to Solid Tumors. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
53	Mechanisms of Viral Degradation of Cellular Signal Transducer and Activator of Transcription 2.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	1
52	Multi-Omics Profiling to Assess Signaling Changes upon VHL Restoration and Identify Putative VHL Substrates in Clear Cell Renal Cell Carcinoma Cell Lines.. <i>Cells</i> , <b>2022</b> , 11,	7.9	1
51	Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma.. <i>Cell Death and Disease</i> , <b>2022</b> , 13, 97	9.8	1
50	Belzutifan: a novel therapy for von Hippel-Lindau disease.. <i>Nature Reviews Nephrology</i> , <b>2022</b> ,	14.9	0
49	Characterization of the pVHL Interactome in Human Testis Using High-Throughput Library Screening.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	



48	The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis.. <i>Genes</i> , <b>2022</b> , 13,	4.2	2
47	PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.. <i>Acta Pharmacologica Sinica</i> , <b>2022</b> ,	8	0
46	Elongin C (ELOC/TCEB1) associated von Hippel-Lindau disease.. <i>Human Molecular Genetics</i> , <b>2022</b> ,	5.6	0
45	Molecular characterization of wheat floret development-related F-box protein (TaF-box2): possible involvement in regulation of Arabidopsis flowering.. <i>Physiologia Plantarum</i> , <b>2022</b> , e13677	4.6	1
44	Hereditary Renal Cell Carcinoma. <i>Kidney Cancer</i> , <b>2022</b> , 1-11	0.6	
43	Table_1.docx. <b>2019</b> ,		
42	Image_1.JPEG. <b>2020</b> ,		
41	Image_2.JPEG. <b>2020</b> ,		
40	Image_3.JPEG. <b>2020</b> ,		
39	Image_4.JPEG. <b>2020</b> ,		
38	Image_5.JPEG. <b>2020</b> ,		
37	Image_6.JPEG. <b>2020</b> ,		
36	Table_1.DOCX. <b>2020</b> ,		
35	Table_2.DOCX. <b>2020</b> ,		
34	Table_3.DOCX. <b>2020</b> ,		
33	Table_4.DOCX. <b>2020</b> ,		
32	Table_5.DOCX. <b>2020</b> ,		
31	Table_6.DOCX. <b>2020</b> ,		

30	Table_7.DOCX. <b>2020</b> ,		
29	Table_8.DOCX. <b>2020</b> ,		
28	Table_1.DOCX. <b>2019</b> ,		
27	Cervical Spine Tumors. <b>2022</b> , 317-335		
26	Human Protein-l-isoaspartate -Methyltransferase Domain-Containing Protein 1 (PCMTD1) Associates with Cullin-RING Ligase Proteins.. <i>Biochemistry</i> , <b>2022</b> ,	3.2	0
25	Large scale genotype- and phenotype-driven machine learning in Von Hippel-Lindau disease.. <i>Human Mutation</i> , <b>2022</b> ,	4.7	1
24	Biophysical and functional study of CRL5, a muscle specific ubiquitin ligase complex.. <i>Scientific Reports</i> , <b>2022</b> , 12, 7820	4.9	0
23	Inhibition of Hypoxia-Inducible Factor Is Sufficient for Growth Suppression of VHL/Tumors. <i>Molecular Cancer Research</i> , <b>2004</b> , 2, 89-95	6.6	174
22	Molecular Cloning and Characterization of the von Hippel-Lindau-Like Protein. <i>Molecular Cancer Research</i> , <b>2004</b> , 2, 43-52	6.6	14
21	A meta-analysis of different von Hippel Lindau mutations: are they related to retinal capillary hemangioblastoma?.		
20	Target Protein Design and Preselection Analysis. <b>2022</b> , 143-154		0
19	Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. <b>2022</b> , 51, 8216-8257		5
18	Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata. 11,		1
17	Clinicopathological and Body Composition Analysis of VHL and TTN Gene Mutations in Clear Cell Renal Cell Carcinoma: An Exploratory Study. <b>2022</b> , 12, 9502		0
16	OsDWD1 E3 ligase-mediated OsNPR1 degradation suppresses basal defense in rice.		1
15	Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel-Lindau gene in the ccRCC.		0
14	Clinical and Genetic Characteristics of Retinal Capillary Hemangioblastoma in Korean Patients.		0
13	Development of genomic instability-associated long non-coding RNA signature: A prognostic risk model of clear cell renal cell carcinoma. 12,		0

- 12 Hereditary Cancer Syndromes: Risk Assessment and Genetic Counseling. 1-28 ○
- 11 Peptide-mediated inhibition of the transcriptional regulator Elongin BC induces apoptosis in cancer cells. ○
- 10 A Structural and Biophysical Perspective of Degradation Activity Through Ternary Complex Formation. **2023**, 107-149 ○
- 9 Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization. ○
- 8 Investigation of germline VHL variants in Iranian patients with retinal capillary hemangioblastoma and genotype-phenotype analysis. 1-7 ○
- 7 Integrating Surgery in the Multidisciplinary Care of Advanced Renal Cell Carcinoma. **2023**, 50, 311-323 ○
- 6 Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation. **2023**, 30, 175-187.e15○
- 5 Role of SOCS and VHL Proteins in Neuronal Differentiation and Development. **2023**, 24, 3880 ○
- 4 E3 ligase autoinhibition by C-degron mimicry maintains C-degron substrate fidelity. **2023**, 83, 770-786.e9 ○
- 3 Downstream Targets of VHL/HIF-1 $\alpha$  Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. **2023**, 15, 1316 1
- 2 Radiogenomics in Renal Cancer Management: Current Evidence and Future Prospects. **2023**, 24, 4615 1
- 1 PROTACing oncoproteins: targeted protein degradation for cancer therapy. **2023**, 22, ○